{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:11:20Z","timestamp":1784164280525,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jphs.2021.08.011","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:09:44Z","timestamp":1630462184000},"page":"6-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma"],"prefix":"10.1016","volume":"148","author":[{"given":"Hironao","family":"Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Morishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ikejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jphs.2021.08.011_bib1","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Canc Res"},{"issue":"3","key":"10.1016\/j.jphs.2021.08.011_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"A\u00a0novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Canc"},{"issue":"9","key":"10.1016\/j.jphs.2021.08.011_bib3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jcph.917","article-title":"Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses","volume":"57","author":"Tamai","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jphs.2021.08.011_bib4","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/cam4.2241","article-title":"Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.jphs.2021.08.011_bib5","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/cancers12071867","article-title":"Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study","volume":"12","author":"Shimose","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.011_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendation for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijien","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.011_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"issue":"6","key":"10.1016\/j.jphs.2021.08.011_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00280-020-04178-x","article-title":"Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma","volume":"86","author":"Hata","year":"2020","journal-title":"Canc Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/17425255.3.1.81","article-title":"Transporter-mediated drug interactions: clinical implications and in\u00a0vitro assessment","volume":"3","author":"Lin","year":"2007","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.clpt.6100459","article-title":"Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans","volume":"84","author":"Yamasaki","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jphs.2021.08.011_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2015.05.008","article-title":"A\u00a0validated LC-MS\/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis","volume":"114","author":"Mano","year":"2015","journal-title":"J\u00a0Pharmaceut Biomed Anal"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib13","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","article-title":"Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer","volume":"9","author":"Ozeki","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jphs.2021.08.011_bib14","first-page":"611","article-title":"C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance","volume":"1","author":"Imai","year":"2002","journal-title":"Mol Canc Therapeut"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","article-title":"Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.jphs.2021.08.011_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/cbt.6.3.3763","article-title":"Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients","volume":"6","author":"Li","year":"2007","journal-title":"Canc Biol Ther"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2021.08.011_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"8","key":"10.1016\/j.jphs.2021.08.011_bib18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00228-020-02879-z","article-title":"Influences of ABC transporter and CYP3A4\/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects","volume":"76","author":"Li","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bcp.12258","article-title":"Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response","volume":"79","author":"Bender","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jphs.2021.08.011_bib20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jhbp.954","article-title":"Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma","volume":"28","author":"Eso","year":"2021","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"1","key":"10.1016\/j.jphs.2021.08.011_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000512239","article-title":"Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea","volume":"10","author":"Goh","year":"2021","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.jphs.2021.08.011_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","article-title":"Cancer cachexia, mechanism and treatment","volume":"7","author":"Aoyagi","year":"2015","journal-title":"World J Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.jphs.2021.08.011_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:01:16Z","timestamp":1761163276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861321000864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1347861321000864"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.08.011","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}